

Evaluation Report for Category B, Subcategory 2.1 Application

Application Number: 2020-1696
Application: New End-use Product (Product Chemistry) - Guarantee
Product: SELECT 1EC HERBICIDE
Registration Number: 34250
Active ingredient (a.i.): Clethodim
PMRA Document Number : 3269848

Purpose of Application

The purpose of this application was to register the new end-use product, SELECT 1EC HERBICIDE for post-emergence control of grasses in broadleaf crops.

Chemistry Assessment

SELECT 1EC HERBICIDE is formulated as an emulsifiable concentrate containing clethodim at a concentration of 120 g/L. This end-use product has a density of 0.931 g/mL and pH of 3.7. The required chemistry data for SELECT 1EC HERBICIDE have been provided, reviewed and found to be acceptable.

Health Assessments

SELECT 1EC HERBICIDE is of low acute oral, dermal and inhalation toxicity. It is non-irritating to the eye and moderately irritating to the skin. It is not a dermal sensitizer.

Dietary and occupational exposure risk assessments were not required for this application.

Environmental Assessment

The environmental risks from exposure to clethodim are acceptable when SELECT 1EC HERBICIDE is used according to label directions.

Value Assessment

The registration of SELECT 1EC HERBICIDE eliminates the need to mix with an adjuvant providing growers with added flexibility when controlling grassy weeds in broadleaf crops.

Value information submitted for review consisted of precedent registrations, data from replicated field trials, and scientific rationales including extrapolations from registered uses. Based on the weight of evidence, the registration of SELECT 1EC HERBICIDE is considered to have acceptable value.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found it sufficient to register SELECT 1EC HERBICIDE.

References

PMRA Document Number	Reference
3117243	2020, H1231bc Product Identity and Composition, Description of Materials Used to Produce the Product, Description of Formulation Process, Discussion of Formation of Impurities, and Certified Limits, DACO: 3.0,3.1,3.1.3,3.1.4,3.2, 3.2.1,3.2.2,3.2.3,3.3.1,3.4,3.4.1 CBI
3117244	2020, Additional Product Chemistry for Select 1EC Herbicide, DACO: 3.1.1, 3.1.2,3.5.4,3.5.5 CBI
3117245	2020, H1231bc Product Identity and Composition, Description of Materials Used to Produce the Product, Description of Formulation Process, Discussion of Formation of Impurities, Certified Limits and Enforcement Analytical Method - Confidential Attachment, DACO: 3.0,3.1,3.2,3.2.1,3.2.2,3.2.3,3.3.1,3.4 CBI
3117246	2017, Development and Validation of an Analytical Method for the Determination of Clethodim in H1231bc, DACO: 3.4.1 CBI
3117247	2020, H1231bc: Physical Properties, DACO: 3.5,3.5.1,3.5.11,3.5.12,3.5.13, 3.5.2,3.5.3,3.5.6,3.5.7,3.5.8,3.5.9 CBI
3117248	2020, H1231bc: Storage Stability & Corrosion, DACO: 3.5.10,3.5.14 CBI
3234737	2018, ARY-0411-07: Storage Stability and Corrosion Characteristics, DACO: 3.5.10 CBI
3117249	2020, Acute Oral Toxicity Study of Clethodim 12% w/v EC (Equivalent to Clethodim 13% w/w) In Rats, DACO: 4.6.1
3117250	2020, Acute Dermal Toxicity Study of Clethodim 12% w/v EC (Equivalent to Clethodim 13% w/w) In Rats, DACO: 4.6.2
3117251	2020, Acute Inhalation Toxicity Study of Clethodim 12% w/v EC (Equivalent to Clethodim 13% w/w) In Rats, DACO: 4.6.3
3117252	2020, Acute Eye Irritation Study of Clethodim 12% w/v EC (Equivalent to Clethodim 13% w/w) In Rabbits, DACO: 4.6.4
3117253	2020, Acute Dermal Irritation Study of Clethodim 12% w/v EC (Equivalent to Clethodim 13% w/w) In Rats, DACO: 4.6.5
3117254	2020, Skin Sensitization Study of Clethodim 12% w/v EC (Equivalent to Clethodim 13% w/w) In Guinea Pigs [Buehler Test Method], DACO: 4.6.6
3117240	2020, VALUE SUMMARY FOR SELECT 1EC, DACO: 10.1,10.2.1,10.2.2,10.2.3.1,10.2.3.3,10.3.1,10.3.2,10.4,10.5.2
3117242	2020, Efficacy and Phytotoxicity Trials for Select 1EC, DACO: 10.2.3.3(B)

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2021

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.

